Description
Non-Fucosylated Anti-Human EphB3 (XPA.04.013) is a glycosylation-modified therapeutic biobetter antibody.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced EphB3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
EPHB3
Full Name
EPH receptor B3
Background
Ephrin receptors and their ligands, the ephrins, mediate numerous developmental processes, particularly in the nervous system. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. The Eph family of receptors are divided into two groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. This gene encodes a receptor for ephrin-B family members.
Alternative Names
EPHB3; EPH receptor B3; ETK2; HEK2; TYRO6; ephrin type-B receptor 3; EK2; EPH-like kinase 2; embryonic kinase 2; human embryo kinase 2; EPH-like tyrosine kinase 2; EPH-like tyrosine kinase-2; tyrosine-protein kinase TYRO6
Gene ID
2049
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
XPA.04.013
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Antibody Indication
Cancer
